The online version of this article (doi:10.1186/1756-9966-33-36) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
SH is fully responsible for the study designing, experiment adjustment and drafting the manuscript. FZ performed most of the experiments involved. QT carried out transfection assays and some protein measurement by Western blot and statistical analysis. SYZ conducted the densitometry, statistical analysis and participated in coordination manuscript. JJW executed the MTT assays, FOXO3a overexpression experiments and statistical analysis. ZYL fulfilled MTT and Western Blot analysis. LLL and WYW coordinated and provided important suggestions including some agents, and critical read the manuscript. All authors read and approved the final manuscript.
Berberine (BBR), a component from traditional Chinese medicine, has been shown to possess anti-tumor activity against a wide spectrum of cancer cells including human lung cancer, but the detailed mechanism underlining this has not been well elucidated.
In this study, the effect of berberine on cell growth and apoptosis were assessed by MTT, flow cytometry and Hoechst 33258 staining assays. The phosphorylation of p38 MAPK and ERK1/2, and expressions of p38 MAPK isoforms α and β, total ERK1/2, p53, FOXO3a and p21 protein were evaluated by Western Blot analysis. Silencing of p38 MAPK isoform α and β, p53, FOXO3a and p21 were performed by siRNA methods. Exogenous expression of FOXO3a was carried out by electroporated transfection assays.
We showed that BBR significantly inhibited growth and induced cell cycle arrest of non small cell lung cancer (NSCLC) cells in the G0/G1 phase in a dose-dependent manner. Furthermore, we found that BBR increased phosphorylation of p38 MAPK and ERK1/2 in a time-dependent and induced protein expression of tumor suppressor p53 and transcription factor FOXO3a in a dose-dependent fashion. The specific inhibitor of p38 MAPK (SB203580), and silencing of p38α MAPK by small interfering RNAs (siRNAs), but not ERK1/2 inhibitor (PD98059) blocked the stimulatory effects of BBR on protein expression of p53 and FOXO3a. Interestingly, inhibition of p53 using one specific inhibitor (Pifithrin-α) and silencing of p53 using siRNAs overcome the inhibitory effect of BBR on cell growth. Silencing of FOXO3a appeared to attenuate the effect of BBR on p53 expression, cell proliferation and apoptosis. Furthermore, BBR induces the protein expression of cell cycle inhibitor p21 (CIP1/WAF1), which was not observed in cells silencing of p53 or FOXO3α gene. Intriguingly, exogenous expression of FOXO3a enhanced the expression of p21 (CIP1/WAF1) and strengthened BBR-induced apoptosis.
Our results show that BBR inhibits proliferation and induces apoptosis of NSCLC cells through activation of p38α MAPK signaling pathway, followed by induction of the protein expression of p53 and FOXO3a. The latter contribute to the BBR-increased p21 (CIP1/WAF1) protein expression. The exogenous FOXO3a, interaction and mutually exclusive events of p53 and FOXO3a augment the overall response of BBR.
Authors’ original file for figure 113046_2013_764_MOESM1_ESM.pdf
Authors’ original file for figure 213046_2013_764_MOESM2_ESM.tiff
Authors’ original file for figure 313046_2013_764_MOESM3_ESM.pdf
Authors’ original file for figure 413046_2013_764_MOESM4_ESM.pdf
Authors’ original file for figure 513046_2013_764_MOESM5_ESM.tiff
Authors’ original file for figure 613046_2013_764_MOESM6_ESM.pdf
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Canc J Clin. 2013, 63 (1): 11-30. 10.3322/caac.21166. CrossRef
Yang Y, Xie Y, Xian L: Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis. J Exp Clin Canc Res. 2013, 32: 15-10.1186/1756-9966-32-15. CrossRef
Milner J: Forms and functions of p53. Semin Canc Biol. 1994, 5 (3): 211-219.
Hann SS, Zheng F, Zhao S: Targeting 3-phosphoinositide-dependent protein kinase 1 by N-acetyl-cysteine through activation of peroxisome proliferators activated receptor alpha in human lung cancer cells, the role of p53 and p65. J Exp Clin Canc Res. 2013, 32: 43-10.1186/1756-9966-32-43. CrossRef
Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, Burgering BM, Medema RH: Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol. 2002, 22 (22): 7842-7852. 10.1128/MCB.22.22.7842-7852.2002. PubMedCentralCrossRefPubMed
Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, Cheng X, Chang KJ, Hsiao CD, Tsai FJ, Tsai CH, Sahin AA, Muller WJ, Mills GB, Yu D, Hortobagyi GN, Hung MC: ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008, 10 (2): 138-148. 10.1038/ncb1676. PubMedCentralCrossRefPubMed
Renault VM, Thekkat PU, Hoang KL, White JL, Brady CA, Kenzelmann Broz D, Venturelli OS, Johnson TM, Oskoui PR, Xuan Z, Santo EE, Zhang MQ, Vogel H, Attardi LD, Brunet A: The pro-longevity gene FoxO3 is a direct target of the p53 tumor suppressor. Oncogene. 2011, 30 (29): 3207-3221. 10.1038/onc.2011.35. PubMedCentralCrossRefPubMed
Yip NK, Ho WS: Berberine induces apoptosis via the mitochondrial pathway in liver cancer cells. Oncol Rep. 2013, 30 (3): 1107-1112. PubMed
Fu L, Chen W, Guo W, Wang J, Tian Y, Shi D, Zhang X, Qiu H, Xiao X, Kang T, Huang W, Wang S, Deng W: Berberine targets AP-2/hTERT, NF-kappaB/COX-2, HIF-1alpha/VEGF and cytochrome-c/caspase signaling to suppress human cancer cell growth. PloS one. 2013, 8 (7): e69240-10.1371/journal.pone.0069240. PubMedCentralCrossRefPubMed
Li J, Cao B, Liu X, Fu X, Xiong Z, Chen L, Sartor O, Dong Y, Zhang H: Berberine suppresses androgen receptor signaling in prostate cancer. Mol Canc Ther. 2011, 10 (8): 1346-1356. 10.1158/1535-7163.MCT-10-0985. CrossRef
Finch AR, Caunt CJ, Perrett RM, Tsaneva-Atanasova K, McArdle CA: Dual specificity phosphatases 10 and 16 are positive regulators of EGF-stimulated ERK activity: indirect regulation of ERK signals by JNK/p38 selective MAPK phosphatases. Cell Signal. 2012, 24 (5): 1002-1011. 10.1016/j.cellsig.2011.12.021. PubMedCentralCrossRefPubMed
Ma LL, Sun WJ, Wang Z, Zh GY, Li P, Fu SB: Effects of silencing of mutant p53 gene in human lung adenocarcinoma cell line Anip973. J Exp Clin Canc Res. 2006, 25 (4): 585-592.
Nemoto S, Fergusson MM, Finkel T: Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Sci. 2004, 306 (5704): 2105-2108. 10.1126/science.1101731. CrossRef
Nanda K, Miyoshi N, Nakamura Y, Shimoji Y, Tamura Y, Nishikawa Y, Uenakai K, Kohno H, Tanaka T: Extract of vinegar “Kurosu” from unpolished rice inhibits the proliferation of human cancer cells. J Exp Clin Canc Res. 2004, 23 (1): 69-75.
Liedtke C, Trautwein C: A dual role of p21 in liver regeneration and hepatocarcinogenesis. Hepatol. 2008, 48 (5): 1713-1714. 10.1002/hep.22588. CrossRef
Zhong Z, Yeow WS, Zou C, Wassell R, Wang C, Pestell RG, Quong JN, Quong AA: Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. Canc Res. 2010, 70 (5): 2105-2114. 10.1158/0008-5472.CAN-08-1108. CrossRef
Shen G, Xu C, Chen C, Hebbar V, Kong AN: p53-independent G1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with induction of p21CIP1 and inhibition of expression of cyclin D1. Canc Chemother Pharmacol. 2006, 57 (3): 317-327. 10.1007/s00280-005-0050-3. CrossRef
- p38α MAPK-mediated induction and interaction of FOXO3a and p53 contribute to the inhibited-growth and induced-apoptosis of human lung adenocarcinoma cells by berberine
- BioMed Central
Journal of Experimental & Clinical Cancer Research
Elektronische ISSN: 1756-9966
Neu im Fachgebiet Onkologie
Mail Icon II